Ikena Oncology (NASDAQ:IKNA – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 294.74% from the company’s current […]
Related Keywords
United States , American , , Ikena Oncology Inc , Millennium Management , Cubist Systematic Strategies , Dimensional Fund Advisors , Virtu Financial , Nasdaq , American International Group Inc , Ikena Oncology , Get Free Report , Oncology Stock Down , International Group , Fund Advisors , Systematic Strategies , Ikena Oncology Daily , Nasdaq Ikna , Vikna , Medical , Reiterated Rating , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.